# Title: Predominance of multidrug-resistant (MDR) bacteria causing urinary tract infections (UTIs) among symptomatic patients in East Africa: a call for action

Authors: Antonio Maldonado-Barragán<sup>1†\*</sup>, Stephen E. Mshana<sup>2†\*</sup>, Katherine Keenan<sup>6</sup>, Xuejia Ke<sup>7</sup>,
Stephen H. Gillespie<sup>1</sup>, John Stelling<sup>3</sup>, John Maina<sup>4</sup>, Joel Bazira<sup>5</sup>, Ivan Muhwezi<sup>5</sup>, Martha F. Mushi<sup>2</sup>,
Dominique L. Green<sup>6</sup>, Mike Kesby<sup>6</sup>, Andy G. Lynch<sup>1</sup>, Wilber Sabiiti<sup>1</sup>, Derek J. Sloan<sup>1</sup>, Alison
Sandeman<sup>1</sup>, John Kiiru<sup>4</sup>, Benon Asiimwe<sup>8</sup>, Matthew T. G. Holden<sup>1</sup>, HATUA consortium.

7

9

8 <sup>†</sup>These authors contributed equally to this work and share first authorship.

# 10 Affiliations:

- 11 <sup>1</sup>School of Medicine, University of St Andrews, St Andrews, Fife, KY16 9TF, UK
- 12 <sup>2</sup>Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and
- 13 Allied Sciences, Mwanza P.O. Box 1464, Tanzania
- 14 <sup>3</sup>Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- 15 <sup>4</sup>Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
- <sup>5</sup>Department of Microbiology and Immunology, Mbarara University of Science and Technology, Mbarara, Uganda
- <sup>6</sup>School of Geography and Sustainable Development, University of St Andrews, St Andrews, KY16 8AL, Fife, UK
- 18 <sup>7</sup>School of Biology, University of St Andrews, St Andrews, KY16 9TH, Fife, UK
- <sup>19</sup> <sup>8</sup>Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda
- 20

## 21 **Corresponding (s) author (s):**

- 22 Antonio Maldonado-Barragán\*; e-mail: maldoantonio@gmail.com
- 23 Stephen E. Mshana\*; e-mail: <u>stephen72mshana@gmail.com</u>
- 24

## 25 HATUA consortium includes everyone listed above, plus:

26 Blandina T. Mmbaga (Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical

- 27 University College, Tanzania), John Mwaniki (KEMRI, Kenya), Stella Neema (Makerere University,
- Uganda), Joseph R. Mwanga (Catholic University of Health and Allied Sciences, Tanzania), Arun
- 29 Gonzales Decano (University of St Andrews, UK), V. Anne Smith (University of St Andrews, UK),
- 30 Alison Elliott (London School of Hygiene & Tropical Medicine, UK), Gibson Kibiki (Africa
- 31 Research Excellence Fund), David Aanensen (University of Oxford, UK).
- 32

## 33 Author contributions

- 34 AM: Formal analysis, Data curation, Writing original draft preparation, Writing review and editing
- SEM: Conceptualisation, Formal analysis, Data curation, Writing original draft preparation, Writing review
   and editing.
- 37 XK: Formal analysis, data curation; Writing review and editing
- 38 KK: Conceptualisation, Formal analysis, data curation; Writing review and editing, supervision
- 39 SG: Methodology; Validation; Writing review and editing
- 40 JS: Methodology; Validation; Writing review and editing
- 41 JM: Methodology; Investigation; Data curation; Writing review and editing
- 42 JB: Methodology; Investigation; Data curation
- 43 IM: Methodology; Investigation; Data curation
- 44 MM: Methodology; Investigation; Data curation
- 45 DLG: Data curation
- 46 MK: Conceptualisation; Methodology; Writing review and editing
- 47 AGL: Conceptualisation; Methodology; Writing review and editing
- 48 WS: Conceptualisation; Methodology; Writing review and editing
- 49 DJS: Conceptualisation; Methodology; Writing review and editing
- 50 AS: Coordinated the study; Writing review and editing
- 51 JK: Conceptualisation; Methodology; Led data collection in Kenya
- 52 BA: Conceptualisation; Methodology; Led data collection in Uganda
- 53 MH: Led project conceptualisation; Methodology, Funding acquisition; Writing review and editing
- 54
- 55
- 56
- 57
- 58
- 59
- ...
- 60

#### 61 Abstract

In low- and middle-income countries, antibiotics are often prescribed for patients with symptoms of 62 urinary tract infections (UTIs) without microbiological confirmation. Inappropriate antibiotic use can 63 contribute to antimicrobial resistance (AMR) and the selection of multi-drug resistant (MDR) 64 bacteria. Data on antibiotic susceptibility patterns of cultured bacteria are important in drafting 65 empirical treatment guidelines and monitoring resistance trends, which can prevent the spread of 66 AMR. In East Africa, antibiotic susceptibility data are sparse. To fill the gap, this study reports 67 common microorganisms and their susceptibility patterns isolated from patients with UTI-like 68 symptoms in Kenya, Tanzania, and Uganda in 2019-2020. Microbiologically confirmed UTI was 69 observed in 2,653 (35.0%) of the 7583 patients studied. The predominant bacteria were Escherichia 70 coli (37.0%), Staphylococcus spp. (26.3%), Klebsiella spp. (5.8%) and Enterococcus spp. (5.5%). E. 71 coli contributed 982 of the isolates with an MDR proportion of 52.2%. Staphylococcus spp. 72 contributed 697 of the isolates with an MDR rate of 60.3%. The overall proportion of MDR bacteria 73 (n=1,153) was 50.9%. MDR bacteria are common causes of UTI in patients attending healthcare 74 centres in East African countries, which emphasizes the need for investment in laboratory culture 75 capacities and diagnostic algorithms to improve accuracy of diagnosis that will lead to appropriate 76 antibiotic uses to prevent and control AMR. 77

78

Keywords: Urinary Tract Infection; Antimicrobial resistance; Antibacterial resistance; Multi-drug
resistance; Pathogen-antibiotic combinations; East Africa.

81 82

#### 83 **1. Introduction**

Increase of antimicrobial resistance (AMR) is currently considered one of the top 10 global public 84 health threats [1]. In 2019, there were an estimated 4.95 million deaths associated with antibacterial 85 resistance (ABR) including 1.27 million deaths directly attributable to ABR [2]. Among all world 86 87 regions, Sub-Saharan Africa has the largest burden of ABR-attributable deaths [2], although most 88 contemporary ABR estimates in that region are based on incredibly sparse data [2,3,4]. This serious threat requires a better assessment of ABR to understand the current and future burden of AMR and 89 90 to direct the use of antibiotics (ABs) more effectively. This motivated the formation of the interdisciplinary consortium "Holistic Approach to Unravel Antibacterial Resistance in East Africa" 91 92 (HATUA), which aimed to explore the burden and drivers of ABR associated with urinary tract infections (UTIs) in three East African countries, Kenya, Tanzania, and Uganda [5]. 93

94

UTI is an inflammatory response of the urothelium to bacterial invasion and is considered the most 95 frequent community-acquired bacterial infection in the world, affecting more than 150 million people 96 per year [6,7]. In addition, UTIs are the third most frequent healthcare-associated infections (HAIs), 97 with approximately one-third of all deaths associated to HAIs [8]. Globally, deaths attributable to and 98 associated with ABR in UTIs in 2019 were approximately 65,000 and 250,000, respectively [2,7]. 99 UTI is the second most frequent reason for using ABs in the community, which can contribute to the 100 emergence of multi-drug resistant (MDR) bacteria [9]. The prevalence of MDR bacteria – defined as 101 102 bacteria with nonsusceptibility to at least one agent in  $\geq 3$  antimicrobial categories [10] – associated

- 103 with UTI has increased worldwide, thus limiting the therapeutic options for the treatment of infections
- 104 caused by those microorganisms [11,12,13].
- 105

In community-acquired UTIs, AB treatment is usually prescribed empirically. The selection of the 106 107 empirical AB is based on surveillance mechanisms addressing the frequency of uropathogens and their antimicrobial resistance profiles. However, culture and susceptibility data for community UTI 108 infections are unavailable in many LIMCs regions such as East Africa, mainly due to limited health 109 service funding, and paucity of microbiology laboratory capacities including limited skilled personnel 110 [2,3,4]. These data are critical for prescribing the appropriate empirical AB, which could contribute 111 to reducing the emergence of MDR bacteria and therefore UTI-associated complications such as 112 pyelonephritis or bacteraemia through more effective treatment [15]. 113

114

115 The main goals of this study are, therefore, to describe the proportion of microbiologically confirmed 116 UTI in symptomatic patients who attended clinics in Kenya, Tanzania, and Uganda, to characterize 117 the main uropathogenic bacteria responsible and their antimicrobial resistance profiles, and to 118 estimate the proportion of MDR bacteria associated with UTIs. The findings presented here can input 119 to UTI empirical treatment guidelines in East Africa, helping to prevent the AMR-associated 120 complications and deaths.

121

## 122 **2. Methods**

123 **2.1. Study design, patient selection, and sample size** 

The sample collection took place between April 2019 and November 2020 in Kenya, Tanzania, and Uganda in different levels of health facilities and locations (Table S1). The study included adults and children ( $\geq$  2 years) with signs and symptoms of UTI (detailed description for inclusion of patients are shown in the supplementary material (Method S1). Self-collected mid-stream clean catch urine samples were obtained from each patient, as described previously [5]. Patients were classified

according to their stay at the recruitment health facilities as outpatient (visits with no overnight stay)
or inpatient (overnight or longer stay). A total of 7,583 patients with symptomatic UTI were recruited
from Kenya (n=1,903), Tanzania (n=3,852), and Uganda (n=1,828) (Figure 1).

132

## 133 2.2. Urine culture and biochemical identification of isolates

A standard disposable sterile plastic loop was used to inoculate 1µl or 10µl of mid-stream urine 134 sample onto cysteine-lactose-electrolyte-deficient (CLED), sheep blood (SBA), and MacConkey 135 agar plates (Oxoid, Basingstoke, UK) [16]. After 18-24 hours of incubation at 37°C under aerobic 136 137 conditions, cultures were quantified. Microbiologically confirmed urinary tract infection (hereafter UTI positive samples) was defined by the presence of  $>10^4$  colony-forming units per millilitre of one 138 or two uropathogens. Contaminated samples (>  $10^4$  CFU/mL growth of more than two different 139 uropathogens or any growth of  $< 10^4$  CFU/mL) and those with no microbial growth were considered 140 UTI negative. In samples containing two possible uropathogens, only the predominant or the most 141 142 probable uropathogen (subjected to the evaluation by an experienced clinical microbiologist) was 143 included in the analysis of the data.

144

In-house methods were used to identify Gram-negative bacteria and included: colonial morphology
on CLED, Blood, and MacConkey agar (Oxoid, Basingstoke, UK), and Triple Sugar Iron agar,
Sulphur Indole and Motility, Citrate, Oxidase, Urease, Voges-Proskauer and Methyl Red tests.
Coagulase, Catalase, Bile-esculin, and Bacitracin-Sulfamethoxazole disc susceptibility tests were
used to confirm the presence of Gram-positive bacteria, which were identified using colony
morphology on SBA.

151

## 152 **2.3.** Antimicrobial susceptibility testing

Antimicrobial susceptibility testing (AST) was performed by the conventional Kirby–Bauer disk 153 diffusion method according to Clinical and Laboratory Standards Institute (CLSI) M02 document 154 [17]. The discs (Oxoid, Basingstoke, UK) tested were ampicillin (10µg), amoxicillin/clavulanic acid 155  $(20/10\mu g)$ , cefoxitin  $(30\mu g)$ , tetracycline  $(30\mu g)$ , trimethoprim  $(5\mu g)$ , ciprofloxacin  $(5\mu g)$ , 156 157 gentamicin (10 $\mu$ g), nitrofurantoin (100 $\mu$ g), ceftriaxone (30 $\mu$ g), ceftazidime (30 $\mu$ g), erythromycin (15µg), linezolid (10µg) and vancomycin (30µg). The susceptibility or non-susceptibility (resistance) 158 to the tested ABs was determined by using the breakpoints (zone diameter interpretive criteria) 159 indicated in the M100 document of CLSI guidelines [18], as further detailed in supplementary Method 160 S2. Those isolates that showed intermediate resistance to a given AB were considered resistant to 161

such AB. Prediction of possible extended-spectrum  $\beta$ -lactamase (ESBL) producers was based on ceftazidime and/or ceftriaxone resistance, following the criteria indicated in the CLSI guidelines [18].

164

# 165 2.4. Definition and analysis of multidrug resistance

MDR bacteria were defined as isolates resistant to at least one agent in three or more classes of antimicrobial agents, following the European Centre for Disease Prevention and Control (ECDC) guidelines [10], with some modifications as specified in supplementary Method S3. MDR rates were calculated by considering the number of MDR isolates divided by the total isolates where valid MDR data were obtained.

171

#### 172 **2.5. Patient characteristics**

A questionnaire was conducted with all patients (or their parents/guardians) which captured
sociodemographic factors including age, gender, and other factors (e.g. education, marital status and
household socioeconomic factors). Selected variables are shown in Table 1.

176

## 177 **2.6. Data management and analysis**

Data were captured using paper forms and electronically, using Epicollect5 mobile application
(https://five.epicollect.net) [19]. Urinalysis, AST and MDR data was linked to the questionnaire data
using anonymous patient identifiers. AB susceptibility/MDR rates were calculated in R Statistical
Software (v4.1.1; R Core Team 2021). Descriptive analysis and χ2-testing with false discovery rate
correction (Benjamini and Yekutieli 2001) were conducted in STATA 16 (StataCorp. 2019. Stata
Statistical Software: Release 16. College Station, TX: StataCorp LLC).

184

## 185 **2.7. Quality control**

*Escherichia coli* ATCC 25922, *E. coli* NCTC 13353 (CTX-M-15 ESBL producer), *Staphylococcus aureus* ATCC 25923, *S. aureus* NCTC 13552 (*mecC*; MRSA), *Pseudomonas aeruginosa* ATCC
49189, *Proteus mirabilis* NCTC 10975, and *Enterococcus faecium* ATCC 51559 (*vanA*; vancomycin
resistant) were used as reference strains for quality control of culture, biochemical identification, and
antimicrobial susceptibility tests.

191

## 192 **3. Results**

## **3.1. Study participants and samples**

A consort diagram of patient recruitment and analysis is shown in Figure 1. A total of 7,583 urine
 samples from non-repetitive patients with suspected UTI were collected in Kenya, Tanzania, and

| 196 | Uganda, of which 7,574 were categorized as either UTI-negative or UTI-positive, according to the          |
|-----|---|
| 197 | results of the urine cultures. Of a total of 2,653 biochemically identified isolates, we obtained a valid |

- 198 AST result for 2,357 bacteria, which were subsequently included in the AST and MDR analysis.
- 199

# 200 **3.2. Demographic features**

Participant characteristics are shown in Table 1. Most were adult outpatients (89.9%) and females
(77%). The modal age category was 25 to 34 years, and those aged 18-34 years contributed more than
half (54.7%) of the total sample.

204

## **3.3. Proportion of microbiologically confirmed UTI**

The overall proportion of microbiologically confirmed UTI across the three countries was 35.0%, being significantly higher in inpatients than in outpatients, in females, in patients recruited in higherlevel facilities, and among patients over 65 years old (Table S3). Kenya reported a UTI proportion of 54.1%, which was higher than the proportion of 29.2% and 27.5% found in Tanzania and Uganda, respectively (Table S3).

211

# 212 **3.4. Identity of isolates from UTI**

A total of 2,653 isolates were characterised from urine samples of UTI-positive patients, 2,416 from outpatients and 237 from inpatients, of which 94.9% corresponded to bacteria, 1.1% to yeast, and 4.0% to isolates whose biochemical identification was not available. Among the bacterial isolates (n=2,518), 62.7% and 37.3% were Gram-negative and Gram-positive bacteria, respectively, of which 91.2% (n=2,297) were identified to at least the genus level.

218

Considering the three countries together (Table 2), *E. coli* was the predominant species (37.0%),
followed by *Staphylococcus* spp. (26.3%), *Klebsiella* spp. (5.8%), and *Enterococcus* spp. (5.5%). By
country, Kenya showed higher proportion of *Staphylococcus* spp. than Tanzania and Uganda, while
Uganda showed higher proportion of *E. coli* than Kenya and Tanzania. Globally, *E. coli*, *Staphylococcus* spp., *Enterococcus* spp. and *Pseudomonas* spp. were more represented in samples
from outpatients than inpatients, while proportions of *Klebsiella* spp. and *Acinetobacter* spp. were
higher in samples from inpatients (Table S4).

226

## 227 3.5. Regional burden of MDR in UTI pathogens

Of a total of 2,266 isolates included in the AST and MDR analysis (Figure 1), n=1,153 (50.9%) were categorized as MDR. By country, MDR rates were similar in Tanzania (60.9%) and Uganda (57.5%)

while Kenya had a lower MDR rate (36.9%) (Table 3). Considering all countries together, the 230 proportion of uropathogens that were classified as MDR was significantly higher in isolates from 231 inpatients, those recruited in lower-level facilities, and in male patients (Table 3). By country, MDR 232 proportions in Kenya and Tanzania were higher in males than in females, but this relationship was 233 reversed in Uganda. By pathogen, *Staphylococcus* spp. showed the higher rates of MDR (60.3%), 234 followed by E. coli (52.2%), Klebsiella spp. (50.6%), Enterococcus spp. (38.1%), and other 235 Enterobacterales (31.2%) (Table 4). Within each pathogen group, isolates from inpatients or males 236 237 exhibited higher MDR rates than isolates from outpatients and females, respectively (Table 4).

238

#### 239 **3.6.** Antibiotic susceptibility and MDR in *Enterobacterales*

The overall resistance rates of *Enterobacterales* ranged from 71.6% for trimethoprim to 7.5% for 240 nitrofurantoin. The proportion of isolates with an ESBL and MDR were 31.4% and 49.5%, 241 respectively (Table 5). Within bacterial groups, the resistance rates of the *E. coli* isolates ranged from 242 74.4% for trimethoprim to 4.1% for nitrofurantoin (Table 5), with an ESBL and MDR proportion of 243 29.3% and 52.2%, respectively. Klebsiella spp. isolates exhibited resistance rates between 93.5% for 244 ampicillin to 14.3% for nitrofurantoin (Table 5) and ESBL and MDR rates of 53.9% and 50.6%, 245 respectively. The resistance rates of other Enterobacterales ranged from 61.8% for trimethoprim to 246 15.1% for gentamicin, displaying ESBL and MDR rates of 21.7% and 30.9%, respectively. 247

248

E. coli from Kenya were less likely to be resistant to ampicillin, amoxicillin/clavulanic acid, 249 trimethoprim, ciprofloxacin, ceftriaxone, and ceftazidime than those from Tanzania and Uganda, 250 while in Tanzania, E. coli resistance to nitrofurantoin was higher than the other countries (Table S5). 251 252 In addition, MDR and ESBL were less common among *E. coli* isolates from Kenya than those from Tanzania and Uganda, while MDR *Klebsiella spp.* were less represented in Uganda than in Tanzania. 253 Regarding other *Enterobacterales*, isolates from Kenya were significantly less likely to be resistant 254 to ampicillin, amoxicillin/clavulanic acid, ceftriaxone and ceftazidime than those from Tanzania and 255 256 Uganda, and also showed lower ESBL and MDR rates. Ugandan isolates showed significantly higher 257 rates of resistance to nitrofurantoin than isolates from other countries (Table S5).

258

The proportion of resistant isolates was generally higher in inpatients (Table S6) than outpatients
(Table S7). Prevalence of ESBL and MDR among inpatient isolates was higher among *E. coli*, *Klebsiella* spp. and other *Enterobacterales* than those from outpatients (Table S6 and S7).

262

# 263 3.7. Antibiotic susceptibility and MDR in Staphylococci and Enterococci

The proportion of resistant *Staphylococcus* spp. isolates ranged from 5.5 % for nitrofurantoin to 81.8% for trimethoprim, with a MDR prevalence of 60.3% (Table 5). The cefoxitin resistance indicating methicillin resistance among staphylococci was 37.5%, 42.4% and 42.9% for Kenya, Tanzania, and Uganda respectively (Table S8). *Staphylococcus* spp. from Kenya showed a higher proportion of linezolid-resistant isolates (23.4%) than the other two countries (5.5%-7.5%) (Table S8). Isolates from Tanzania had the greatest proportion with MDR (72.3%).

270

For *Enterococcus* spp., the overall resistance rates ranged from 8.8% for linezolid to 69.8% for erythromycin, with a MDR prevalence of 38.1% (Table 5). Comparisons among countries revealed that *Enterococcus* sp. isolates from Kenya were less resistant to tetracycline and nitrofurantoin, and more resistant to linezolid than isolates from Tanzania and Uganda, with no significant differences in MDR rates (Table S8).

276

Staphylococcus spp. isolates from inpatients (Table S9) showed higher resistance than isolates from
outpatients (Table S10), except for ABs ciprofloxacin, trimethoprim and tetracycline, displaying also
increased MDR (72.1% vs. 59.5%) (Tables S9 and S10). *Enterococcus* spp. from inpatients were
more resistant to ciprofloxacin, erythromycin and tetracycline, and showed higher MDR than
outpatients (68.8% vs. 34.4%) (Tables S9 and S10).

282

#### 283 **4. Discussion**

This study samples the patterns of ABR in bacteria associated with UTIs in symptomatic patients in 284 East Africa. Our main finding is that ABR of the main uropathogens isolated from UTIs (E. coli, 285 Staphylococcus spp., Klebsiella spp., and Enterococcus spp.) are severely high. Further, 286 approximately half of the bacterial pathogens isolated from UTIs have MDR. That rate was much 287 higher among inpatients (which we assume are predominantly hospital-acquired UTI) than in 288 outpatients (which we assume are predominantly community-acquired UTIs), as has been described 289 290 previously [20,21]. These alarming data provide further empirical evidence to enrich the findings of 291 recent studies describing the high morbidity and mortality burden from ABR in Eastern sub-Saharan Africa [2]. 292

293

The high proportion of MDR in UTI could suggest a previous record of inappropriate AB use in Kenya, Tanzania, and Uganda, which is often considered to be one of the key drivers of AMR. This could be caused by (a) the scarcity of microbiology and AB susceptibility data in this region [2,3,4] which can hamper the management of more appropriate empirical treatment for UTIs, and (b) AB

self-treatment and the prevalence of over-the-counter sales of ABs in the community, widespread in
LMICs [22,23,24]. Suboptimal management of treatment and the community transmission of MDR
bacteria promoted by crowded and less sanitary living conditions, more common in low- and middleincome countries (LMICs) [25], could explain the high proportions of MDR bacteria and the tendency
in the study cohort to come straight to clinic [26].

303

In addition, we found differences among countries, with Kenya presenting lower percentage of MDR bacteria (36.9%) than Tanzania (60.9%) and Uganda (57.5%). Worthy of special attention are the high MDR rates of *E. coli* (>66.0%) found in Tanzania and Uganda, as well as MDR *Klebsiella* (62.2%), *Staphylococcus* (72.3%) and *Enterococcus* (46.6%) species observed in Tanzania, which were much higher than in the other countries. These results emphasise the importance of implementing or reviewing country-specific empirical AB recommendations, which could increase AB efficacy and reduce the burden of AMR according to the resistance rates of each country [27].

311

Globally, our results fill a crucial data gap which we hope will: (a) feed into guidelines for UTI empirical treatment, (b) provide vital surveillance data for East Africa and indeed the wider Sub-Saharan region, a region with one of the highest ABR-mortality burdens in the world, and c) contribute to development of interventions to monitor and counter the threat of ABR across the region through improved diagnostics and surveillance.

317

The sparsity of data about the prevalence of resistance for key pathogen-antibiotic combinations in 318 LMICs is a limiting factor for drafting empirical treatment guidelines which can promote appropriate 319 320 prescription hence hindering the selection of the resistant pathogens [2,3,4]. In this study, we have found a high prevalence of the most insidious AB-pathogen combinations i.e. third-generation 321 cephalosporin (3GC)-resistant E. coli (29.3%), fluoroquinolone-resistant E. coli (45.8%), 3GC-322 resistant Klebsiella spp. (53.9%), methicillin-resistant staphylococci (39.7%), fluoroquinolone-323 324 resistant Enterococcus spp. (40.1%), and vancomycin-resistant Enterococcus spp. (37.2%). However, 325 we observed systematic variations across country settings, with the Kenyan samples showing the lowest rate of resistance to these ABs, which suggest that recommendations for using a specific 326 327 empirical AB should be tailored according to each country [27]. The high proportion of fluoroquinolone-resistant *E. coli* and fluoroquinolone-resistant *Enterococcus* spp. found in this study, 328 329 which are in the top six of the most lethal AB-combination in UTI [7], advise against the empirical use of this AB, whose use in treatment of uncomplicated UTI is no longer recommended by WHO 330 331 [28,29]. The clinical guidelines of Tanzania and Uganda recommended ciprofloxacin as first or

second line ABs for the treatment of uncomplicated UTI in outpatients [30,31,32], which could
explain the higher fluoroquinolone resistance observed in these two countries than those observed in
Kenya.

Methicillin-resistant S. aureus was the most lethal drug-pathogen combination in 2019 in the world 335 [2], being in the top ten of resistance-attributable deaths in UTI [7]. Although in our study 336 staphylococci were not analysed to species level, we found an overall rate of methicillin (cefoxitin) 337 resistance of 39.7%. This contrasts with global estimations in sub-Saharan Africa, which has been 338 339 recently described as one of the lowest in the world (5%) [2]. Our study has revealed Staphylococcus spp. as the second most frequent genus in UTI, which is in line with current evidence that point 340 towards a major role of this species as a common cause of UTI [33,34,35]. Although we cannot rule 341 out contamination with Staphylococcus spp. in UTI samples, the fact that nearly 2 of every 3 isolates 342 were MDR, and  $\approx 40\%$  were resistant to cefoxitin, should be considered for managing *Staphylococcus* 343 spp. as true causing agents of UTI. 344

345

Amoxicillin/clavulanic acid is among the ABs commonly used to treat uncomplicated UTI. In this study, we found a high level of resistance (37.3%-47.1%) to amoxicillin/clavulanic acid in *Enterobacterales*, which could endanger its future empirical use for treatment of UTIs [36] as happened with amoxicillin alone, whose use in uncomplicated UTI is no longer recommended [29].

In addition, the overall resistance to the folate pathway inhibitor trimethoprim was exceptionally high 350 (53.9%-74.4%) in isolates from order *Enterobacterales*, while resistance to nitrofurantoin was low. 351 This trend has been reported in UTIs worldwide, which has led to the prioritization of the use of 352 nitrofurantoin over trimethoprim as the first-line treatment for UTI [37], including East Africa 353 354 [30,31,32]. In 2021, however, the WHO added single-agent trimethoprim as a recommendation for the treatment of uncomplicated UTI [29], whose empirical use in East Africa (with a trimethoprim-355 resistance E. coli rate of until 84.1% in Tanzania), would make that AB poorly effective for the 356 treatment of UTI in that region. 357

358

The study has some limitations. In the design of the HATUA we endeavoured to provide a consistent study framework across the three countries and the three sites within each country where patients were recruited and their samples were processed and analysed. Standardization of methods and operating procedures were applied across the consortium [5] and used by the Kenyan, Tanzanian, and Ugandan chapters of HATUA. However, even with these in place we cannot rule out that some biases in sampling practices or patient populations studied will have occurred.

365

Within each country three sites were chosen that had three distinct socio-demographical 366 characteristics and represented a different type of site. This was done in order capture the burden of 367 AMR in UTIs across different community settings in each country. Whilst each country selected sites 368 that were representative of each site type, and provided some level of sociodemographic 369 comparability across countries for the study, there is variation that a study of this scale introduces 370 that means that the populations are not equivalent due to geographic, climatic, ethnic and cultural 371 factors. In this regard we note that across the three countries there are differences in the demographic 372 373 profiles of the patients recruited. For example, in Kenya more recruitment occurred at higher level health facilities, and the cohort had a greater proportion of patients under the age of 35 years in 374 comparison to those of the other countries. We cannot therefore exclude the introduction of bias that 375 may influence some of the observed microbiological results and some of the differences seen between 376 countries. Recognising this, the interpretation of the results should reflect that they do not necessarily 377 represent true country-level differences across the region, as the sampling within the countries is 378 limited to three sites and is not representative of the countries as a whole. 379

380

With such a large, multi-site study, and need for comparability, there have been some inevitable trade-381 offs between depth and breadth, and as a result for most of the isolates, only their identification to 382 genus level is shown. As samples from outpatients were self-collected, there was a risk of 383 contamination in the samples, which could help explain the high levels of *Staphylococcus* spp. found 384 in this study. Although a wide range of the most commonly used/relevant ABs for UTI in the region 385 was tested, this did not include all possible ABs, which could have led to an underestimation of the 386 true MDR proportions, and therefore our estimates of the burden of AMR on patients with UTIs are 387 388 conservative.

389

#### **5.** Conclusions

This multi-site standardised study describes how approximately half of UTI patients that attended to 391 392 our recruitment centres in Kenya, Tanzania, and Uganda exhibit MDR bacteria. Several of the most hazardous pathogen-antibiotic combinations (third-generation cephalosporins and fluoroquinolones 393 resistant E. coli; methicillin-resistant staphylococci (MRS); third-generation cephalosporin-resistant 394 K. pneumoniae; vancomycin-resistant enterococci; multi-drug resistant bacteria) were detected at 395 high proportions in UTI, which severely limits the effectiveness of currently used ABs to treat this 396 397 common infection. These findings should feed directly into guidelines for empiric AB treatment of UTI in East Africa. More broadly, we emphasize the need for urgent investment in routine AMR 398 399 surveillance programs, expansion of diagnostic laboratory capacities and diagnostic algorithms to

facilitate antimicrobial stewardship and call for greater commitment from policymakers to counterthe threat of AMR.

401 the threat of Ar

402

## 403 Acknowledgements

We thank all the patients who participated in the HATUA study and the field and laboratory teams in each of the three countries.

406

## 407 Funding

408 HATUA is a Global Context Consortia Award (MR/S004785/1) funded by the National Institute for

409 Health Research, Medical Research Council, and the Department of Health and Social Care. This UK

410 funded award is part of the EDCTP2 programme supported by the European Union.

411

# 412 Competing interests

- 413 None
- 414

# 415 Ethical approval

416 The studies involving human participants were reviewed and approved by University of St Andrews,

417 UK (number MD14548, 10/09/19); National Institute for Medical Research, Tanzania (number 2831,


updated 26/07/19); CUHAS/BMC Research Ethics and Review Committee (number CREC 418 /266/2018, updated on 02/2019); Mbeya Medical Research and Ethics Committee (number SZEC-419 2439/R.A/V.1/303030); Kilimanjaro Christian Medical College, Tanzania (number 2293, updated 420 14/08/19); Uganda National Council for Science and Technology (number HS2406, 18/06/18); 421 Makerere University, Uganda (number 514, 25/04/18); and Kenya Medical Research Institute 422 423 (04/06/19,Scientific and Ethics Review Committee (SERU) number KEMRI/SERU/CMR/P00112/3865 V.1.2). The patients/participants provided their written informed 424 425 consent to participate in this study.


426

420

427 428

429





| Variables/Country           | Kenya<br>n (%) | Tanzania<br>n (%) | Uganda<br>n (%) | Total<br>n (%) |
|-----------------------------|----------------|-------------------|-----------------|----------------|
| Patient type                |                |                   |                 |                |
| Outpatient                  | 1754(92.4)     | 3552(92.2)        | 1815(99.5)      | 7121(94.0)     |
| Inpatient                   | 144(7.6)       | 300(7.8)          | 9(0.5)          | 453(6.0)       |
| Gender                      |                |                   |                 |                |
| Male                        | 348(18.3)      | 1097(28.5)        | 295(16.2)       | 1740(23.0)     |
| Female                      | 1550(81.7)     | 2754(71.5)        | 1529(83.8)      | 5833(77.0)     |
| Missing                     | NA             | 1(0.0)            | NA              | 1(0.0)         |
| Age in years                |                |                   |                 |                |
| <18                         | 79(4.2)        | 343(8.9)          | 62(3.4)         | 484(6.4)       |
| 18-24                       | 493(26.0)      | 718(18.6)         | 573(31.4)       | 1784(23.6)     |
| 25-34                       | 837(44.1)      | 950(24.7)         | 573(31.4)       | 2360(31.2)     |
| 35-44                       | 294(15.5)      | 550(14.3)         | 304(16.7)       | 1148(15.2)     |
| 45-54                       | 97(5.1)        | 425(11.0)         | 173(9.5)        | 695(9.2)       |
| 55-64                       | 43(2.3)        | 321(8.3)          | 71(3.9)         | 435(5.7)       |
| 65-74                       | 35(1.8)        | 281(7.3)          | 43(2.4)         | 359(4.7)       |
| 75 and above                | 20(1.1)        | 261(6.8)          | 22(1.2)         | 303(4.0)       |
| Missing                     | 0(0)           | 3(0.1)            | 3(0.2)          | 6(0.1)         |
| Hospital level <sup>1</sup> |                |                   |                 |                |
| Level 2 (low)               | 0(0)           | 309 (8.0)         | 394(21.6)       | 703(9.3)       |
| Level 3                     | 384(20.2)      | 2152(55.9)        | 1023(56.1)      | 3559(47.0)     |
| Level 4                     | 486(25.6)      | 366(9.5)          | 143(7.8)        | 995(13.1)      |
| Level 5 /6 (high)           | 1028(54.2)     | 1025(26.6)        | 263(14.4)       | 2316(30.6)     |
| Missing                     | 0(0)           | 0(0)              | 1(0.1)          | 1(0.0)         |
| TOTAL                       | 1898 (100.0)   | 3852 (100.0)      | 1824 (100.0)    | 7574 (100.0)   |

| Table 1. Characteristics of the patient | s with symptoms | of UTI at the time of recruitment |
|---|-----------------|-----------------------------------|
|---|-----------------|-----------------------------------|

<sup>1</sup>In all three countries, lower levels (1-3) refer to primary care, dispensaries, or community health centres. Level 4 typically refers to primary referral facilities or specialist health care facilities. Level 5 (and 6 in Kenyan) are higher level/tertiary facilities.

**Table 2**. Distribution of significant microorganisms isolated from specimens of symptomatic patients

 with UTI (UTI positive patients), according to the country.

| Country                                     | Country Kenya |        | Т                        | Tanzania |      | Uganda      |     |      | All 3 countries |      |      |             |
|---|---------------|--------|--------------------------|----------|------|-------------|-----|------|-----------------|------|------|-------------|
| Microbial Isolates                          | n             | $\%^1$ | Prev<br>(%) <sup>2</sup> | n        | %    | Prev<br>(%) | n   | %    | Prev<br>(%)     | n    | %    | Prev<br>(%) |
| Escherichia coli                            | 317           | 30.9   | 16.7                     | 402      | 35.8 | 10.4        | 263 | 52.4 | 14.4            | 982  | 37.0 | 13.0        |
| Klebsiella spp.                             | 0             | 0      | 0                        | 90       | 8.0  | 2.3         | 64  | 12.7 | 3.5             | 154  | 5.8  | 2.0         |
| Proteus spp.                                | 69            | 6.7    | 3.6                      | 13       | 1.2  | 0.3         | 15  | 3.0  | 0.8             | 97   | 3.7  | 1.3         |
| Acinetobacter spp.                          | 8             | 0.8    | 0.4                      | 19       | 1.7  | 0.5         | 5   | 1.0  | 0.3             | 32   | 1.2  | 0.4         |
| Pseudomonas spp.                            | 8             | 0.8    | 0.4                      | 41       | 3.6  | 1.1         | 1   | 0.2  | 0.1             | 50   | 1.9  | 0.7         |
| Miscellaneous<br>Gram-negative <sup>3</sup> | 101           | 9.8    | 5.3                      | 111      | 9.9  | 2.9         | 52  | 10.4 | 2.9             | 264  | 10.0 | 3.5         |
| Staphylococcus spp.                         | 387           | 37.7   | 20.4                     | 220      | 19.6 | 5.7         | 91  | 18.1 | 5.0             | 698  | 26.3 | 9.2         |
| Enterococcus spp.                           | 86            | 8.4    | 4.5                      | 58       | 5.2  | 1.5         | 3   | 0.6  | 0.2             | 147  | 5.5  | 1.9         |
| Miscellaneous<br>Gram-positive <sup>4</sup> | 31            | 3.0    | 1.6                      | 55       | 4.9  | 1.4         | 8   | 1.6  | 0.4             | 94   | 3.5  | 1.2         |
| Yeast                                       | 2             | 0.2    | 0.1                      | 28       | 1.1  | 0.7         | 0   | 0.0  | 0.0             | 30   | 1.1  | 0.4         |
| Missing species data                        | 18            | 1.8    | 0.9                      | 87       | 7.7  | 2.3         | 0   | 0.0  | 0.0             | 105  | 4.0  | 1.4         |
| Total                                       | 1027          | 100    | 54.1                     | 1124     | 100  | 29.2        | 502 | 100  | 27.5            | 2653 | 100  | 35.0        |

 $^{1}$ % = percentage of isolates corresponding to that species, from that country (for example in the first column, calculated by 317/1027\*100).

<sup>2</sup>Prev= prevalence proportion (e.g. number of *E. coli* isolates with respect to the total number of urine specimens that were cultured in that country). For example, the third column is calculated by 317/1898\*100.

<sup>3</sup> Across all three countries, this comprises *Aeromonas* spp. (n=1), *Citrobacter* spp. (n=16), *Enterobacter* spp. (n=24), *Moraxella* spp. (n=1), *Morganella* spp. (n=6), *Pantoea* spp. (n=2), *Providencia* spp. (n=2), *Salmonella* spp. (n=2), *Serratia* spp. (n=4), *Shigella* spp. (n=1), *Stenotrophomonas* spp. (n=1), and undetermined Gramnegative bacteria (n=113)

<sup>4</sup>Across all three countries, this comprises *Bacillus* spp. (n=19), *Clostridium* spp. (n=1), *Corynebacterium* spp. (n=1), *Lactobacillus* spp. (n=6), *Streptococcus* spp. (n=50), and undetermined Gram-positive bacteria (n=17).

| <b>Table 3.</b> Prevalence of multi-drug resistant (MDR) bacteria in UTI positive samples by country, |
|---|
| and according to patient type, hospital level, gender, and age.                                       |

|                    | MDR <sup>1</sup> n (%) |                   |                 |                        |  |  |  |  |  |  |  |
|--------------------|------------------------|-------------------|-----------------|------------------------|--|--|--|--|--|--|--|
| Variable           | Kenya<br>n (%)         | Tanzania<br>n (%) | Uganda<br>n (%) | All countries<br>n (%) |  |  |  |  |  |  |  |
| Patient type       | n (70)                 | <b>n</b> (70)     | <b>n</b> (70)   | <b>n</b> (70)          |  |  |  |  |  |  |  |
| Outpatient         | 291(35.4)              | 466(58.8)         | 258(57.3)       | 1015(49.2)             |  |  |  |  |  |  |  |
| Inpatient          | 36(56.3)               | 100(73.0)         | 2(100)          | 138(68.0)              |  |  |  |  |  |  |  |
| $\chi^2$ , p value | 9.7, p=0.014           | 9.24, p=0.019     | 0.25, p=1.000   | 25.1, p<0.001          |  |  |  |  |  |  |  |
| Facility level     | -                      | -                 | -               | -                      |  |  |  |  |  |  |  |
| Level 2/3          | 55(35.7)               | 328(59.2)         | 188(54.3)       | 571(54.2)              |  |  |  |  |  |  |  |
| Level 4            | 109 (37.0)             | 55(59.1)          | 26(76.5)        | 190(45.2)              |  |  |  |  |  |  |  |
| Level 5 /6         | 168(38.1)              | 183(64.9)         | 46(63.9)        | 397(49.9)              |  |  |  |  |  |  |  |
| $\chi^2$ , p value | 0.27, p=1.000          | 2.67, p=0.728     | 7.62, p=0.183   | 10.7, p<0.001          |  |  |  |  |  |  |  |
| Sex                | -                      | -                 | -               | -                      |  |  |  |  |  |  |  |
| Male               | 40(42.1)               | 174(68.5)         | 30(53.6)        | 244(60.2)              |  |  |  |  |  |  |  |
| Female             | 287(36.3)              | 392(58.2)         | 230(58.1)       | 909(48.9)              |  |  |  |  |  |  |  |
| $\chi^2$ , p value | 1.41, p=0.740          | 9.85, p=0.030     | 0.24, p=1.000   | 18.8, p<0.001          |  |  |  |  |  |  |  |
| Age                |                        |                   |                 |                        |  |  |  |  |  |  |  |
| <18                | 20(45.5)               | 42(64.6)          | 6(66.7)         | 68(57.3)               |  |  |  |  |  |  |  |
| 18-24              | 84(34.1)               | 95(56.9)          | 73(52.1)        | 252(45.5)              |  |  |  |  |  |  |  |
| 25-34              | 135(35.3)              | 116(62.0)         | 84(57.5)        | 335(46.8)              |  |  |  |  |  |  |  |
| 35-44              | 53(39.3)               | 70(54.3)          | 44(66.7)        | 167(50.6)              |  |  |  |  |  |  |  |
| 45-54              | 19(50.0)               | 59(59.0)          | 35(60.3)        | 113(57.6)              |  |  |  |  |  |  |  |
| 55-64              | 9(56.3)                | 53(66.3)          | 9(64.3)         | 71(64.5)               |  |  |  |  |  |  |  |
| 65-74              | 8(44.4)                | 66(66.0)          | 3(30.0)         | 77(60.2)               |  |  |  |  |  |  |  |
| 75 and above       | 4(40.0)                | 65(64.4)          | 4(57.1)         | 73(61.9)               |  |  |  |  |  |  |  |
| $\chi^2$ , p value | 8.81, p=0.740          | 6.71, p=0.96      | 7.76, p=1.000   | 35.3, p<0.001          |  |  |  |  |  |  |  |
| TOTAL MDR          | 327(36.9)              | 566(60.9)         | 260(57.5)       | 1153(50.9)             |  |  |  |  |  |  |  |
| Total isolates     | 885                    | 929               | 452             | 2266                   |  |  |  |  |  |  |  |

<sup>1</sup> MDR was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section (see Table S2). % is the prevalence of MDR, calculated by dividing the number of isolates that are MDR (n) by the number of isolates tested for MDR of each category and country.

**Table 4.** Prevalence of multi-drug resistant (MDR) bacteria in UTI positive samples for selected species, according to patient type, age, and gender.

|                   | Escherichia coli | Klebsiella spp. | MDR <sup>1</sup> n (%)<br>Other<br>Entero-<br>bacterales <sup>2</sup> | Staphylococcus<br>spp. | Enterococcus<br>spp. |
|-------------------|------------------|-----------------|---|------------------------|----------------------|
| Patient type      |                  |                 |   |                        |                      |
| Outpatient        | 460 (50.8)       | 57 (44.9)       | 39 (28.3)   | 389 (59.5)             | 45 (34.4)            |
| Inpatient         | 53 (69.7)        | 21 (77.8)       | 9 (56.3)  | 31 (72.1)              | 11 (68.8)            |
| $\chi^2$ p value  | 9.36, p=0.006    | 8.36, p=0.020   | 4.01, p=0.120   | 2.11, p=0.803          | 5.58, p=0.064        |
| Age               |                  |                 |   |                        |                      |
| Adult             | 481 (51.7)       | 71 (49.7)       | 43 (30.9)   | 403 (59.9)             | 52 (37.7)            |
| Child             | 31 (62.0)        | 6 (60.0)        | 5 (33.3)  | 17 (70.8)              | 4 (44.4)             |
| $\chi^2$ p value  | 1.64, p=0.367    | 0.09, p=1.000   | 0.01, p=1.000   | 0.71, p=0.970          | 0.01, p=1.000        |
| Gender            | -                | -               | -   | -                      | -                    |
| Male              | 107 (71.3)       | 37 (63.8)       | 23 (44.2)   | 43 (64.2)              | 17 (58.6)            |
| Female            | 406 (48.8)       | 41 (42.7)       | 25 (24.5)   | 377 (59.8)             | 39 (33.1)            |
| $\chi^2$ p value  | 25.7, p<0.001    | 5.61, p=0.048   | 5.35, p=0.113   | 0.39, p=0.970          | 5.14, p=0.064        |
| Total MDR         | 513 (52.2)       | 78 (50.6)       | 48 (31.2)   | 420 (60.3)             | 56 (38.1)            |
| Total<br>isolates | 982              | 154             | 154   | 697                    | 147                  |

<sup>1</sup> MDR was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section (see Table S2). % is the prevalence of MDR, calculated by dividing the number of isolates that are MDR (n) by the number of isolates tested for MDR of each category and selected species.

<sup>2</sup>Other *Enterobacterales* includes *Citrobacter*, *Enterobacter*, *Morganella*, *Proteus*, *Providencia*, *Pantoea*, *Salmonella*, *Serratia* and *Shigella* species.

|                                 | Enterobacterales |                | Enterobacterales Escherichia Klebsiella coli spp. |     | Other<br>Enterobacterales <sup>1</sup> |     | Staphylococcus<br>spp. |     | Enterococcus<br>spp. |     |      |     |
|---------------------------------|------------------|----------------|---|-----|--|-----|------------------------|-----|----------------------|-----|------|-----|
|                                 | % <sup>2</sup>   | n <sup>3</sup> | %   | n   | %                                      | n   | %                      | n   | %                    | n   | %    | n   |
| Ampicillin                      | 65.9             | 1289           | 64.5  | 981 | 93.5                                   | 154 | 46.8                   | 154 | $NA^4$               | NA  | NA   | NA  |
| Amoxicillin/<br>clavulanic acid | 40.7             | 1276           | 38.1  | 970 | 60.1                                   | 153 | 37.3                   | 153 | NA                   | NA  | NA   | NA  |
| Ceftazidime                     | 24.0             | 1277           | 22.7  | 971 | 41.2                                   | 153 | 15.7                   | 153 | NA                   | NA  | NA   | NA  |
| Ceftriaxone                     | 30.2             | 1287           | 28.5  | 979 | 51.3                                   | 154 | 20.1                   | 154 | NA                   | NA  | NA   | NA  |
| Ciprofloxacin                   | 44.8             | 1289           | 45.8  | 982 | 43.5                                   | 154 | 39.2                   | 153 | 38.2                 | 696 | 40.1 | 147 |
| Gentamicin                      | 21.5             | 1170           | 22.1  | 900 | 24.8                                   | 129 | 14.9                   | 141 | 20.9                 | 669 | NA   | NA  |
| Nitrofurantoin                  | 7.5              | 1286           | 4.1   | 978 | 14.3                                   | 154 | 22.7                   | 154 | 5.5                  | 692 | 9.5  | 147 |
| Trimethoprim                    | 71.6             | 1289           | 74.4  | 981 | 63.0                                   | 154 | 62.3                   | 154 | 81.8                 | 696 | NA   | NA  |
| Cefoxitin                       | NA               | NA             | NA  | NA  | NA                                     | NA  | NA                     | NA  | 39.7                 | 692 | NA   | NA  |
| Linezolid                       | NA               | NA             | NA  | NA  | NA                                     | NA  | NA                     | NA  | 15.9                 | 661 | 8.8  | 136 |
| Erythromycin                    | NA               | NA             | NA  | NA  | NA                                     | NA  | NA                     | NA  | 72.5                 | 662 | 69.8 | 139 |
| Tetracycline                    | NA               | NA             | NA  | NA  | NA                                     | NA  | NA                     | NA  | 48.0                 | 671 | 50.3 | 145 |
| Vancomycin                      | NA               | NA             | NA  | NA  | NA                                     | NA  | NA                     | NA  | NA                   | NA  | 37.2 | 137 |
| ESBL <sup>5</sup>               | 31.4             | 1290           | 29.3  | 982 | 53.9                                   | 154 | 22.1                   | 154 | NA                   | NA  | NA   | NA  |
| MDR <sup>6</sup>                | 49.5             | 1290           | 52.2  | 982 | 50.6                                   | 154 | 31.2                   | 154 | 60.3                 | 697 | 38.1 | 147 |

Table 5. Antibiotic susceptibility, ESBL and MDR rates of Enterobacterales and relevant Gram-

positive uropathogens

<sup>1</sup> Other Enterobacterales includes Citrobacter, Enterobacter, Morganella, Proteus, Providencia, Pantoea, Salmonella, Serratia and Shigella species.

<sup>2</sup>% is the frequency of non-susceptible isolates, expressed in percentage.

<sup>3</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup> not applicable (NA), the antibiotic was not tested in those isolates.

<sup>5</sup>Possible producers of extended-spectrum  $\beta$ -lactamase (ESBL) were determined by considering the resistance to antibiotics Ceftazidime and Ceftriaxone, according to CLSI guidelines [17].

<sup>6</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

# **Appendix. Supplementary materials**

#### Method S1. Patient selection/Case definition

The study included adults and children ( $\geq 2$  years) with signs and symptoms of urinary tract infections. Patients attended to the health facilities to seek treatment for UTI-like symptoms or for other causes that gave the doctor reason to believe that they might also (or actually) have a UTI. Specifically, the study enrolled: (a) pregnant women with fever and at least one of the following symptoms, lower abdominal pain, flank/back pain, or strong-smelling urine; (b) pregnant women with at least one urinary symptom, i.e., dysuria, pyuria or haematuria; (c) non-pregnant women or men with fever and at least one of the following symptoms, lower abdominal pain, flank/back pain, or men with at least one urinary symptom, i.e., dysuria, pyuria or haematuria; (c) non-pregnant women or men with fever and at least one of the following symptoms, lower abdominal pain, flank/back pain or strong-smelling urine; (d) non-pregnant women or men with at least one urinary symptom, i.e., frequency, dysuria, pyuria, haematuria or urgency [1,2,3]. In addition, the study enrolled all children aged two years and above that complied with at least one of the following criteria: (a) fever and at least one of: vomiting, abdominal pain, flank/back pain, strong-smelling urine or enuresis; (b) at least one of: costovertebral angle tenderness, abdominal or suprapubic tenderness to palpation, palpable bladder or dribbling/poor stream [4].

#### Method S2. Antimicrobial susceptibility testing (AST)

The susceptibility or non-susceptibility (resistance) to the tested antibiotics was determined by using the breakpoints (zone diameter interpretive criteria) indicated in the CLSI guidelines [5] with the following modifications. For nitrofurantoin and linezolid, the European Committee on Antimicrobial Susceptibility Testing [6] breakpoints were used. For *Acinetobacter* spp., susceptibility to amoxicillin/clavulanic acid and trimethoprim was determined using the breakpoints for *Enterobacterales*. For *Staphylococcus* spp., methicillin resistance (non-susceptibility to cefoxitin) was calculated using the breakpoints for *S. epidermidis* and *Staphylococcus* spp. For *Pseudomonas* spp., breakpoints for *Pseudomonas aeruginosa* were applied.

## Method S3. Definition and analysis of Multidrug resistance (MDR)

MDR bacteria were defined as isolates resistant to at least one agent in three or more classes of antimicrobial agents, following the European Centre for Disease Prevention and Control (ECDC) guidelines [7], with some modifications. Thus, nitrofurantoin and trimethoprim, two antibiotics routinely used for treating UTIs that are not included in the ECDC tables [7], were also considered for estimating MDR (Table S2). In addition, for those species/genera not incorporated in the ECDC,

i.e. *Salmonella*, *Shigella* and *Streptococcus*, the MDR rates were calculated following the same rule as described above, but considering the resistance to a selected pool of tested antibiotics (Table S2). Those *Staphylococcus* spp. isolates that were resistant to cefoxitin (methicillin-resistant), were not automatically considered MDR, and were subjected to the rule of being resistant to at least one agent in three or more classes of antimicrobial agents. In those isolates with intrinsic resistance to a given antibiotic, such antibiotic was not considered for calculating MDR. By means of this approach, isolates from UTIs were classified as MDR or non-MDR. MDR rates were calculated by considering the number of MDR isolates divided by the total isolates where valid MDR data were obtained.

#### References

- [1] Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract Infections. Microbiol Spectr 2016;4:10.1128/microbiolspec.UTI-0002-2012. https://doi.org/10.1128/microbiolspec.UTI-0002-2012.
- [2] Bonkat G, Pickard R, Bartoletti R, Bruyère F, Geerlings SE, Wagenlehner F, et al. EAU guidelines on urological infections. European Association of Urology 2017;18:22-6
- [3] Orenstein R, Wong ES. Urinary tract infections in adults. Am Fam Physician 1999;59:1225-1237. PMID: 10088877.
- [4] Ginsburg CM, McCracken GH Jr. Urinary tract infections in young infants. Pediatrics 1982;69:409-12. PMID: 7070887.
- [5] Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81. <u>https://doi.org/10.1111/j.1469-0691.2011.03570.x</u>.
- [6] CLSI. 2021. Performance standards for antimicrobial susceptibility testing, M100, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- [7] EUCAST. 2021. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0.

| Country/site      | Number of facilities | Source of funding  | Levels recruited from <sup>1</sup> |
|-------------------|----------------------|--------------------|------------------------------------|
| Kenya             |                      |                    |                                    |
| Makueni           | 1                    | Public             | 5                                  |
| Nairobi           | 4                    | Public and private | 3, 4, 5, 6                         |
| Nanyuki           | 1                    | Public             | 4                                  |
| Tanzania          |                      |                    |                                    |
| Kilimanjaro/Moshi | 3                    | Public and private | 2, 3, 5                            |
| Mbeya             | 2                    | Public and private | 3, 4                               |
| Mwanza            | 5                    | Public and private | 2, 3, 5                            |
| Uganda            |                      | Ĩ                  |                                    |
| Mbarara           | 3                    | Public             | 3, 5                               |
| Nakapiripirit     | 3                    | Public             | 2, 3                               |
| Nakasongola       | 3                    | Public and private | 3, 4                               |

<sup>1</sup> Levels of facilities are identified in each country following the Kenya Health Policy 2014-2013

(http://publications.universalhealth2030.org/uploads/kenya\_health\_policy\_2014\_to\_2030.pdf), Tanzania fifth health sector strategic plan (HSSP V) 2021-2026

(https://p4h.world/en/node/11813#:~:text=2026%20%7C%20P4H%20Network-

,Tanzania%20fifth%20health%20sector%20strategic%20plan%20(HSSPV)%2D%202021%2D2026,coverage%20(UH C)%20by%202030) and the Ugandan Hospital and Health Centre IV census survey 2014

In all three countries, lower levels (1-3) refer to primary care, dispensaries or community health centres. Level 4 typically refers to primary referral facilities or specialist health care facilities. Level 5 (and 6 in Kenyan) are higher level/tertiary facilities.

| Gram negative      | Amoxicillin/<br>clavulanate<br>(AMC) | Ampicillin<br>(AMP) | Ceftazidime/<br>Ceftriaxone<br>(CAZ/CRO) | Ciprofloxacin<br>(CIP) | Gentamicin<br>(GEN) | Nitrofurantoi<br>n<br>(NIT) | Trimethoprim<br>(TMP) |
|--------------------|--------------------------------------|---------------------|--|------------------------|---------------------|-----------------------------|-----------------------|
| E. coli            | AMC                                  | AMP                 | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Shigella spp.      | AMC                                  | AMP                 | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Proteus spp.       | AMC                                  | AMP                 | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Salmonella spp.    | AMC                                  | AMP                 | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Serratia spp.      | -                                    | -                   | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Klebsiella spp.    | AMC                                  | -                   | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Citrobacter spp.   | -                                    | -                   | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Enterobacter spp.  | -                                    | -                   | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Morganella spp.    | -                                    | -                   | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Pantoea spp.       | -                                    | -                   | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Providencia spp.   | -                                    | -                   | CAZ/CRO                                  | CIP                    | GEN                 | NIT                         | TMP                   |
| Acinetobacter spp. | -                                    | -                   | CAZ/CRO                                  | CIP                    | GEN                 | -                           | TMP                   |
| Pseudomonas spp.   | -                                    | -                   | CAZ                                      | CIP                    | GEN                 | -                           | -                     |

Table S2. Antibiotics considered for MDR calculations.

| Gram positive              | Cefoxitin<br>(FOX) | Erythromycin<br>(ERY) | Linezolid<br>(LNZ) | Ciprofloxacin<br>(CIP) | Gentamicin<br>(GEN) | Nitrofurantoi<br>n<br>(NIT) | Trimethoprim<br>(TMP) | Tetracyclin<br>e<br>(TCY) | Vancomyci<br>n<br>(VAN) |
|----------------------------|--------------------|-----------------------|--------------------|------------------------|---------------------|-----------------------------|-----------------------|---------------------------|-------------------------|
| <i>Staphylococcus</i> spp. | FOX                | ERY                   | -                  | CIP                    | GEN                 | NIT                         | ТМР                   | TCY                       | -                       |
| Enterococcus spp.          | -                  | ERY                   | LNZ                | CIP                    | -                   | NIT                         | -                     | TCY                       | VAN                     |
| Streptococcus spp.         | -                  | ERY                   | LNZ                | -                      | -                   | NIT                         | -                     | TCY                       | VAN                     |

|                                 |                             | N/% w                          | vith UTI                     |                                       |
|---------------------------------|-----------------------------|--------------------------------|------------------------------|---------------------------------------|
| Variables/Country               | Kenya<br>n (%) <sup>1</sup> | Tanzania<br>n (%) <sup>1</sup> | Uganda<br>n (%) <sup>1</sup> | All 3 countries<br>n (%) <sup>1</sup> |
| Patient type                    |                             |                                |                              |                                       |
| Outpatient                      | 943(53.8)                   | 974(27.4)                      | 499(27.5)                    | 2416(33.9)                            |
| Inpatient                       | 84(58.3)                    | 150(50.0)                      | 3(33.3)                      | 237(52.3)                             |
| $\chi^2$ , p value <sup>2</sup> | 0.94, p=0.690               | 67.2, p<0.001                  | 0.1, p=1.000                 | 62.48, p<0.001                        |
| Gender                          |                             |                                |                              |                                       |
| Male                            | 111(31.9)                   | 305(27.8)                      | 64(21.7)                     | 480(27.6)                             |
| Female                          | 916(59.1)                   | 818(29.7)                      | 438(28.6)                    | 2172(37.2)                            |
| $\chi^2$ , p value <sup>2</sup> | 69.1, p<0.001               | 15.2, p=0.004                  | 7.7, p=0.217                 | 190.6, p<0.001                        |
| Hospital level                  |                             |                                |                              |                                       |
| Level 2                         | 0                           | 88(28.5)                       | 126(32.0)                    | 214(30.4)                             |
| Level 3                         | 162(42.2)                   | 585(27.2)                      | 259(25.3)                    | 1006(28.3)                            |
| Level 4                         | 336(69.1)                   | 104(28.4)                      | 37(25.9)                     | 477(47.9)                             |
| Level 5/6                       | 529(51.4)                   | 347(33.9)                      | 80(30.4)                     | 956(41.3)                             |
| $\chi 2$ , p value <sup>2</sup> | 83.6, p<0.001               | 3.8, p=0.312                   | 5.6, p=0.14                  | 56.7, p<0.001                         |
| Age                             |                             |                                |                              |                                       |
| <18                             | 51(64.6)                    | 75(21.9)                       | 11(17.7)                     | 137(28.3)                             |
| 18-24                           | 286(58.0)                   | 211(29.4)                      | 155(27.1)                    | 652(36.5)                             |
| 25-34                           | 436(52.1)                   | 243(25.6)                      | 159(27.8)                    | 838(35.5)                             |
| 35-44                           | 148(50.3)                   | 150(27.3)                      | 75(24.7)                     | 373(32.5)                             |
| 45-54                           | 49(50.5)                    | 111(26.1)                      | 62(35.8)                     | 222(31.9)                             |
| 55-64                           | 19(44.2)                    | 95(29.6)                       | 17(23.9)                     | 131(30.1)                             |
| 65-74                           | 23(65.7)                    | 111(39.5)                      | 12(27.9)                     | 146(40.7)                             |
| 75 and above                    | 15(75.0)                    | 127(48.7)                      | 9(40.9)                      | 151(49.8)                             |
| $\chi^2$ , p value <sup>2</sup> | 17.2, p=0.045               | 80.2, p<0.001                  | 12.7, p=0.22                 | 56.6, p<0.001                         |
| Total                           | 1027(54.1)                  | 1124(29.2)                     | 502(27.5)                    | 2653(35.0)                            |

Table S3. Prevalence of UTI according to patient type, gender, hospital level age, and country.

<sup>1</sup> % is the prevalence of UTI positive samples, calculated by dividing the number of UTI positive samples by the total number of urine samples cultured (n). A sample was considered UTI-positive if presented  $>10^4$  CFU/mL of one or two uropathogens.

<sup>2</sup>Ch-squared testing adjusted for false discovery rate (as described in the methods).

| Country                                     | 0   | Kenya<br>Jutpatie |                          | J   | Kenya<br>Inpatien |             |     | Fanzani<br>Jutpatie |             |     | Fanzani<br>Inpatien |             | 0   | Uganda<br>Dutpatie |             |   | Uganda<br>Inpatien |             |      | 3 count<br>outpatie |             |     | 3 count<br>Inpatier |             |
|---|-----|-------------------|--------------------------|-----|-------------------|-------------|-----|---------------------|-------------|-----|---------------------|-------------|-----|--------------------|-------------|---|--------------------|-------------|------|---------------------|-------------|-----|---------------------|-------------|
| Microbial Isolates                          | n   | % <sup>1</sup>    | Prev<br>(%) <sup>2</sup> | n   | %                 | Prev<br>(%) | n   | %                   | Prev<br>(%) | n   | %                   | Prev<br>(%) | n   | %                  | Prev<br>(%) | n | %                  | Prev<br>(%) | n    | %                   | Prev<br>(%) | n   | %                   | Prev<br>(%) |
| Escherichia coli                            | 294 | 31.2              | 16.9                     | 23  | 27.4              | 16.0        | 350 | 35.9                | 9.9         | 52  | 34.7                | 17.3        | 262 | 52.5               | 14.4        | 1 | 33.3               | 11.1        | 906  | 37.5                | 12.8        | 76  | 32.1                | 16.8        |
| Klebsiella spp.                             | 0.0 | 0.0               | 0.0                      | 0.0 | 0.0               | 0.0         | 64  | 6.6                 | 1.8         | 26  | 17.3                | 8.7         | 63  | 12.6               | 3.5         | 1 | 33.3               | 11.1        | 127  | 5.3                 | 1.8         | 27  | 11.4                | 6.0         |
| Proteus spp.                                | 66  | 7.0               | 3.8                      | 3   | 3.6               | 2.1         | 12  | 1.2                 | 0.3         | 1   | 0.7                 | 0.3         | 15  | 3.0                | 0.8         | 0 | 0.0                | 0.0         | 93   | 3.8                 | 1.3         | 4   | 1.7                 | 0.9         |
| Acinetobacter spp.                          | 7   | 0.7               | 0.4                      | 1   | 1.2               | 0.7         | 14  | 1.4                 | 0.4         | 5   | 3.3                 | 1.7         | 5   | 1.0                | 0.3         | 0 | 0.0                | 0.0         | 26   | 1.1                 | 0.4         | 6   | 2.5                 | 1.3         |
| Pseudomonas<br>aeruginosa                   | 6   | 0.6               | 0.3                      | 2   | 2.4               | 1.4         | 25  | 2.6                 | 0.7         | 16  | 10.7                | 5.3         | 1   | 0.2                | 0.1         | 0 | 0.0                | 0.0         | 32   | 1.3                 | 0.4         | 18  | 7.6                 | 4.0         |
| Miscellaneous<br>Gram-negative <sup>3</sup> | 87  | 9.2               | 5.0                      | 14  | 16.7              | 9.7         | 94  | 9.7                 | 2.6         | 17  | 11.3                | 5.7         | 51  | 10.2               | 2.8         | 1 | 33.3               | 11.1        | 232  | 9.6                 | 3.3         | 32  | 13.5                | 7.1         |
| <i>Staphylococcus</i> spp.                  | 359 | 38.1              | 20.6                     | 28  | 33.3              | 19.4        | 205 | 21.0                | 5.8         | 15  | 10.0                | 5.0         | 91  | 18.2               | 5.0         | 0 | 0.0                | 0.0         | 655  | 27.1                | 9.2         | 43  | 18.1                | 9.5         |
| Enterococcus spp.                           | 81  | 8.6               | 4.7                      | 5   | 6.0               | 3.5         | 47  | 4.8                 | 1.3         | 11  | 7.3                 | 3.7         | 3   | 0.6                | 0.2         | 0 | 0.0                | 0.0         | 131  | 5.4                 | 1.9         | 16  | 6.8                 | 3.5         |
| Miscellaneous<br>Gram-positive <sup>4</sup> | 28  | 3.0               | 1.6                      | 3   | 3.6               | 2.1         | 54  | 5.5                 | 1.5         | 1   | 0.7                 | 0.3         | 8   | 1.6                | 0.4         | 0 | 0.0                | 0.0         | 90   | 3.7                 | 1.3         | 4   | 1.7                 | 0.9         |
| Yeast                                       | 2   | 0.2               | 0.1                      | 0   | 0.0               | 0.0         | 25  | 2.6                 | 0.7         | 3   | 2.0                 | 1.0         | 0   | 0.0                | 0.0         | 0 | 0.0                | 0.0         | 27   | 1.1                 | 0.4         | 3   | 1.3                 | 0.7         |
| Missing species data                        | 13  | 1.4               | 0.7                      | 5   | 6.0               | 3.5         | 84  | 8.6                 | 2.4         | 3   | 2.0                 | 1.0         | 0   | 0.0                | 0.0         | 0 | 0.0                | 0.0         | 97   | 4.0                 | 1.4         | 8   | 3.4                 | 1.8         |
| Total                                       | 943 | 100               | 53.8                     | 84  | 100               | 58.3        | 974 | 100                 | 27.4        | 150 | 100                 | 50.0        | 499 | 100                | 27.5        | 3 | 100                | 33.3        | 2416 | 100                 | 33.9        | 237 | 100                 | 52.3        |

Table S4. Distribution of significant microorganisms isolated from specimens of symptomatic patients with UTI (UTI positive patients),

according to the country and the type of patient (Outpatient or Inpatient).

 $^{1}$ % = percentage of isolates corresponding to that species, from that country and patient type (for example in the first column, calculated by 294/943\*100)  $^{2}$ Prev= prevalence proportion (e.g. number of *E. coli* isolates with respect to the total number of urine specimens that were cultured in that country, for that type of patient. For example, the third column is calculated by 294/1752\*100.

<sup>3</sup> This comprises *Aeromonas* spp. (n=1), *Citrobacter* spp. (n=16), *Enterobacter* spp. (n=24), *Moraxella* spp. (n=1), *Morganella* spp. (n=6), *Pantoea* spp. (n=2), *Providencia* spp. (n=2), *Salmonella* spp. (n=2), *Serratia* spp. (n=4), *Shigella* spp. (n=1), *Stenotrophomonas* spp. (n=1), and undetermined Gram-negative bacteria (n=115)

<sup>4</sup> This comprises *Bacillus* spp. (n=19), *Clostridium* spp. (n=1), *Corynebacterium* spp. (n=1), *Lactobacillus* spp. (n=6), *Streptococcus* spp. (n=50), and undetermined Gram-positive bacteria (n=16).

|                                 |                |       | E    | scheri | chia co | oli |            |              |    |     | k    | lebsie | <i>lla</i> spp | ).  |             |     |      |     | Other | Enter | obacte | rales <sup>1</sup> |             |     |
|---------------------------------|----------------|-------|------|--------|---------|-----|------------|--------------|----|-----|------|--------|----------------|-----|-------------|-----|------|-----|-------|-------|--------|--------------------|-------------|-----|
|                                 | Ke             | nya   | Tanz | zania  | Uga     | nda | Th<br>coun | ree<br>tries | Ke | nya | Tanz | ania   | Uga            | nda | Th:<br>coun |     | Kei  | nya | Tanz  | zania | Uga    | nda                | Th:<br>coun |     |
|                                 | % <sup>2</sup> | $n^3$ | %    | n      | %       | n   | %          | n            | %  | n   | %    | n      | %              | n   | %           | n   | %    | n   | %     | n     | %      | n                  | %           | n   |
| Ampicillin                      | 21.8           | 317   | 87.1 | 402    | 81.7    | 262 | 64.5       | 981          | NA | NA  | 92.2 | 90     | 95.3           | 64  | 93.5        | 154 | 11.5 | 78  | 84.3  | 51    | 80.0   | 25                 | 46.8        | 154 |
| Amoxicillin-<br>clavulanic acid | 17.4           | 316   | 43.0 | 402    | 56.3    | 252 | 38.1       | 970          | NA | NA  | 58.9 | 90     | 61.9           | 63  | 60.1        | 153 | 10.3 | 78  | 64.7  | 51    | 66.7   | 24                 | 37.3        | 153 |
| Ceftazidime                     | 8.5            | 317   | 28.1 | 402    | 31.7    | 252 | 22.7       | 971          | NA | NA  | 47.8 | 90     | 31.7           | 63  | 41.2        | 153 | 3.8  | 78  | 23.5  | 51    | 37.5   | 24                 | 15.7        | 153 |
| Ceftriaxone                     | 9.2            | 315   | 32.1 | 402    | 46.2    | 262 | 28.5       | 979          | NA | NA  | 52.2 | 90     | 50.0           | 64  | 51.3        | 154 | 5.1  | 78  | 25.5  | 51    | 56.0   | 25                 | 20.1        | 154 |
| Ciprofloxacin                   | 30.0           | 317   | 57.0 | 402    | 47.9    | 263 | 45.8       | 982          | NA | NA  | 55.6 | 90     | 26.6           | 64  | 43.5        | 154 | 33.8 | 77  | 45.1  | 51    | 44.0   | 25                 | 39.2        | 153 |
| Gentamicin                      | 16.9           | 314   | 27.6 | 402    | 19.0    | 184 | 22.1       | 900          | NA | NA  | 31.1 | 90     | 10.3           | 39  | 24.8        | 129 | 11.8 | 76  | 21.6  | 51    | 7.1    | 14                 | 14.9        | 141 |
| Nitrofurantoin                  | 2.9            | 313   | 6.7  | 402    | 1.5     | 263 | 4.1        | 978          | NA | NA  | 18.9 | 90     | 7.8            | 64  | 14.3        | 154 | 10.3 | 78  | 31.4  | 51    | 44.0   | 25                 | 22.7        | 154 |
| Trimethoprim                    | 57.9           | 316   | 84.1 | 402    | 79.5    | 263 | 74.4       | 981          | NA | NA  | 68.9 | 90     | 54.7           | 64  | 63.0        | 154 | 65.4 | 78  | 62.7  | 51    | 52.0   | 25                 | 62.3        | 154 |
| ESBL <sup>4</sup>               | 9.5            | 317   | 32.6 | 402    | 48.3    | 263 | 29.3       | 982          | NA | NA  | 53.3 | 90     | 54.7           | 64  | 53.9        | 154 | 6.4  | 78  | 29.4  | 51    | 56.0   | 25                 | 22.1        | 154 |
| MDR <sup>5</sup>                | 22.7           | 317   | 66.4 | 402    | 66.2    | 263 | 52.2       | 982          | NA | NA  | 62.2 | 90     | 34.4           | 64  | 50.6        | 154 | 19.2 | 78  | 43.1  | 51    | 44.0   | 25                 | 31.2        | 154 |

Table S5. Antibiotic susceptibility, ESBL and MDR rates of Enterobacterales

<sup>1</sup> Other Enterobacterales includes Citrobacter, Enterobacter, Morganella, Proteus, Providencia, Pantoea, Salmonella, Serratia and Shigella species.

<sup>2</sup>% is the frequency of non-susceptible isolates, expressed in percentage.
<sup>3</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup> Possible producers of extended-spectrum  $\beta$ -lactamase (ESBL) were determined by considering the resistance to antibiotics Ceftazidime and Ceftriaxone, according to CLSI guidelines [17].

<sup>5</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

|                                 |      | E              | scherio | chia co | oli (out | patien | t)          |     |    | K   | lebsiel | la spj | o. (outp | atien | nt)        |     |      | Ot | her <i>Ent</i> | teroba | acteral | es <sup>1</sup> (0 | utpatie | nt)              |
|---------------------------------|------|----------------|---------|---------|----------|--------|-------------|-----|----|-----|---------|--------|----------|-------|------------|-----|------|----|----------------|--------|---------|--------------------|---------|------------------|
| Country                         | Ker  | iya            | Tanz    | ania    | Uga      | nda    | Thi<br>coun |     | Ke | nya | Tanza   | ania   | Ugar     | nda   | Th<br>coun |     | Ken  | ya | Tanza          | ania   | Ugar    | nda                | -       | Three<br>untries |
|                                 | %²   | n <sup>3</sup> | %       | n       | %        | n      | %           | n   | %  | n   | %       | n      | %        | n     | %          | n   | %    | n  | %              | n      | %       | n                  | %       | n                |
| Ampicillin                      | 21.1 | 294            | 85.7    | 350     | 81.6     | 261    | 63.5        | 905 | NA | NA  | 93.8    | 64     | 95.2     | 63    | 94.5       | 127 | 11.0 | 73 | 82.5           | 40     | 80      | 25                 | 44.2    | 138              |
| Amoxicillin/<br>clavulanic acid | 17.1 | 293            | 39.1    | 350     | 56.6     | 251    | 36.8        | 894 | NA | NA  | 54.7    | 64     | 61.3     | 62    | 57.9       | 126 | 9.6  | 73 | 57.5           | 40     | 66.7    | 24                 | 33.6    | 137              |
| Ceftazidime                     | 7.5  | 294            | 22.6    | 350     | 31.9     | 251    | 20.2        | 895 | NA | NA  | 35.9    | 64     | 30.6     | 62    | 33.3       | 126 | 1.4  | 73 | 15.0           | 40     | 37.5    | 24                 | 11.7    | 137              |
| Ceftriaxone                     | 8.2  | 293            | 26.0    | 350     | 46.0     | 261    | 26.0        | 904 | NA | NA  | 42.2    | 64     | 49.2     | 63    | 45.7       | 127 | 2.7  | 73 | 17.5           | 40     | 56.0    | 25                 | 16.7    | 138              |
| Ciprofloxacin                   | 29.6 | 294            | 54.0    | 350     | 47.7     | 262    | 44.3        | 906 | NA | NA  | 50      | 64     | 25.4     | 63    | 37.8       | 127 | 31.9 | 72 | 42.5           | 40     | 44.0    | 25                 | 37.2    | 137              |
| Gentamicin                      | 14.7 | 292            | 24.3    | 350     | 19.0     | 184    | 19.7        | 826 | NA | NA  | 23.4    | 64     | 10.3     | 39    | 18.4       | 103 | 9.9  | 71 | 15.0           | 40     | 7.1     | 14                 | 11.2    | 125              |
| Nitrofurantoin                  | 2.1  | 291            | 4.9     | 350     | 1.5      | 262    | 3.0         | 903 | NA | NA  | 15.6    | 64     | 7.9      | 63    | 11.8       | 127 | 11.0 | 73 | 32.5           | 40     | 44.0    | 25                 | 23.2    | 138              |
| Trimethoprim                    | 59.0 | 293            | 83.4    | 350     | 79.4     | 262    | 74.4        | 905 | NA | NA  | 60.9    | 64     | 54.0     | 63    | 57.5       | 127 | 64.4 | 73 | 62.5           | 40     | 52.0    | 25                 | 61.6    | 138              |
| ESBL <sup>4</sup>               | 8.5  | 294            | 26.6    | 350     | 48.1     | 262    | 26.9        | 906 | NA | NA  | 43.8    | 64     | 54.0     | 63    | 48.8       | 127 | 2.7  | 73 | 22.5           | 40     | 56.0    | 25                 | 18.1    | 138              |
| MDR <sup>5</sup>                | 21.4 | 294            | 64.0    | 350     | 66.0     | 262    | 50.8        | 906 | NA | NA  | 56.3    | 64     | 33.3     | 63    | 44.9       | 127 | 16.4 | 73 | 40             | 40     | 44.0    | 25                 | 28.3    | 138              |

Table S6. Antibiotic susceptibility, ESBL and MDR rates of relevant Enterobacterales isolated from outpatients with UTI.

<sup>1</sup> Other Enterobacterales includes Citrobacter, Enterobacter, Morganella, Proteus, Providencia, Pantoea, Salmonella, Serratia and Shigella species.

<sup>2</sup>% is the frequency of non-susceptible isolates, expressed in percentage.

 $^{3}$  n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup>Possible producers of extended-spectrum  $\beta$ -lactamase (ESBL) were determined by considering the resistance to antibiotics Ceftazidime and Ceftriaxone, according to CLSI guidelines [17].

<sup>5</sup> Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10].

|                                 |                | Ŀ              | Escheri | chia c | <i>oli</i> (inj | patien | t)           |    |    | 1   | Klebsiel | la sp | p. (inp | atient | )            |    | Oth | er E | nteroba | cteral | es <sup>1</sup> (inpa | tient) |
|---------------------------------|----------------|----------------|---------|--------|-----------------|--------|--------------|----|----|-----|----------|-------|---------|--------|--------------|----|-----|------|---------|--------|-----------------------|--------|
| Country                         | Ken            | ya             | Tanz    | ania   | Uga             | nda    | Thr<br>count |    | Ke | nya | Tanza    | ania  | Uga     | nda    | Thr<br>count |    | Ker | nya  | Tanza   | ania   | Thr<br>Count          |        |
|                                 | % <sup>3</sup> | n <sup>4</sup> | %       | n      | %               | n      | %            | n  | %  | n   | %        | n     | %       | n      | %            | n  | %   | n    | %       | n      | %                     | n      |
| Ampicillin                      | 30.4           | 23             | 96.2    | 52     | 100             | 1      | 76.3         | 76 | NA | NA  | 88.5     | 26    | 100     | 1      | 88.9         | 27 | 20  | 5    | 90.9    | 11     | 68.8                  | 16     |
| Amoxicillin/<br>clavulanic acid | 21.7           | 23             | 69.2    | 52     | 0               | 1      | 53.9         | 76 | NA | NA  | 69.2     | 26    | 100     | 1      | 70.4         | 27 | 20  | 5    | 90.9    | 11     | 68.8                  | 16     |
| Ceftazidime                     | 21.7           | 23             | 65.4    | 52     | 0               | 1      | 51.3         | 76 | NA | NA  | 76.9     | 26    | 100     | 1      | 77.8         | 27 | 40  | 5    | 54.5    | 11     | 50                    | 16     |
| Ceftriaxone                     | 22.7           | 22             | 73.1    | 52     | 100             | 1      | 58.7         | 75 | NA | NA  | 76.9     | 26    | 100     | 1      | 77.8         | 27 | 40  | 5    | 54.5    | 11     | 50                    | 16     |
| Ciprofloxacin                   | 34.8           | 23             | 76.9    | 52     | 100             | 1      | 64.5         | 76 | NA | NA  | 69.2     | 26    | 100     | 1      | 70.4         | 27 | 60  | 5    | 54.5    | 11     | 56.3                  | 16     |
| Gentamicin                      | 45.5           | 22             | 50      | 52     | NA <sup>5</sup> | NA     | 48.6         | 74 | NA | NA  | 50       | 26    | NA      | NA     | 50.0         | 26 | 40  | 5    | 45.5    | 11     | 43.8                  | 16     |
| Nitrofurantoin                  | 13.6           | 22             | 19.2    | 52     | 0               | 1      | 17.3         | 75 | NA | NA  | 26.9     | 26    | 0       | 1      | 25.9         | 27 | 0   | 5    | 27.3    | 11     | 18.8                  | 16     |
| Trimethoprim                    | 43.5           | 23             | 88.5    | 52     | 100             | 1      | 75.0         | 76 | NA | NA  | 88.5     | 26    | 100     | 1      | 88.9         | 27 | 80  | 5    | 63.6    | 11     | 68.8                  | 16     |
| ESBL <sup>6</sup>               | 21.7           | 23             | 73.1    | 52     | 100             | 1      | 57.9         | 76 | NA | NA  | 76.9     | 26    | 100     | 1      | 77.8         | 27 | 60  | 5    | 54.5    | 11     | 56.3                  | 16     |
| MDR <sup>7</sup>                | 39.1           | 23             | 82.7    | 52     | 100             | 1      | 69.7         | 76 | NA | NA  | 76.9     | 26    | 100     | 1      | 77.8         | 27 | 60  | 5    | 54.5    | 11     | 56.3                  | 16     |

Table S7. Antibiotic susceptibility, ESBL and MDR rates of relevant Enterobacterales isolated from inpatients with UTI.

<sup>1</sup> Other Enterobacterales includes Citrobacter, Enterobacter, Morganella, Proteus, Providencia, Pantoea, Salmonella, Serratia and Shigella species.

<sup>2</sup>No Enterobacterales were isolated from Uganda inpatients

<sup>2</sup>% is the frequency of non-susceptible isolates, expressed in percentage.

<sup>3</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup> NA: not applicable.

<sup>5</sup>Possible producers of extended-spectrum  $\beta$ -lactamase (ESBL) were determined by considering the resistance to antibiotics Ceftazidime and Ceftriaxone, according to CLSI guidelines [17].

<sup>6</sup>Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

|                  |                       |                | Stap | hyloc | occus s | spp. |             |     |      |     | En   | teroco | <i>ccus</i> sp | op. |             |     |
|------------------|-----------------------|----------------|------|-------|---------|------|-------------|-----|------|-----|------|--------|----------------|-----|-------------|-----|
|                  | Kei                   | iya            | Tanz | ania  | Uga     | nda  | Th:<br>coun |     | Kei  | nya | Tanz | ania   | Uga            | nda | Th:<br>coun |     |
|                  | <b>%</b> <sup>1</sup> | n <sup>2</sup> | %    | n     | %       | n    | %           | n   | %    | n   | %    | n      | %              | n   | %           | n   |
| Cefoxitin        | 37.5                  | 384            | 42.4 | 217   | 42.9    | 91   | 39.7        | 692 | NA   | NA  | NA   | NA     | NA             | NA  | NA          | NA  |
| Ciprofloxacin    | 29.4                  | 385            | 50.9 | 220   | 45.1    | 91   | 38.2        | 696 | 33.7 | 86  | 48.3 | 58     | 66.7           | 3   | 40.1        | 147 |
| Nitrofurantoin   | 5.5                   | 381            | 6.4  | 220   | 3.3     | 91   | 5.5         | 692 | 4.7  | 86  | 15.5 | 58     | 33.3           | 3   | 9.5         | 147 |
| Trimethoprim     | 78.4                  |                |      | 220   | 87.9    | 91   | 81.8        | 696 | NA   | NA  | NA   | NA     | NA             | NA  | NA          | NA  |
| Gentamicin       | 18.2                  | 385            | 24.1 | 220   | 26.6    | 64   | 20.9        | 669 | NA   | NA  | NA   | NA     | NA             | NA  | NA          | NA  |
| Linezolid        | 23.4                  | 376            | 5.5  | 220   | 7.7     | 65   | 15.9        | 661 | 14.6 | 82  | 0.0  | 52     | 0.0            | 2   | 8.8         | 136 |
| Erythromycin     | 68.7                  | 377            | 79.1 | 220   | 72.3    | 65   | 72.5        | 662 | 67.1 | 82  | 74.5 | 55     | 50.0           | 2   | 69.8        | 139 |
| Tetracycline     | 41.5                  | 386            | 53.6 | 220   | 67.7    | 65   | 48.0        | 671 | 37.6 | 85  | 69.0 | 58     | 50.0           | 2   | 50.3        | 145 |
| Vancomycin       | NA                    | NA             | NA   | NA    | NA      | NA   | NA          | NA  | 42.5 | 80  | 30.9 | 55     | 0.0            | 2   | 37.2        | 137 |
| MDR <sup>3</sup> | 54.7                  | 386            | 72.3 | 220   | 54.9    | 91   | 60.3        | 697 | 32.6 | 86  | 46.6 | 58     | 33.3           | 3   | 38.1        | 147 |

Table S8. Antibiotic susceptibility and MDR rates of relevant Gram-positive uropathogens.

 $^{1}$  % is the frequency of non-susceptible isolates, expressed in percentage.  $^{2}$  n is the total number of isolates that were tested for a specific antibiotic.

<sup>3</sup>Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

|                  |                       |                | Staphyl | ococcus | spp. (ou | tpatien | t)       |          |                 |     | Entero | coccus | spp. (out | patient | )        |          |
|------------------|-----------------------|----------------|---------|---------|----------|---------|----------|----------|-----------------|-----|--------|--------|-----------|---------|----------|----------|
| Country          | Ker                   | nya            | Tanz    | ania    | Ugar     | nda     | Three co | ountries | Ken             | iya | Tanz   | ania   | Ugar      | nda     | Three co | ountries |
|                  | <b>%</b> <sup>1</sup> | n <sup>2</sup> | %       | n       | %        | n       | %        | n        | %               | n   | %      | n      | %         | n       | %        | n        |
| Cefoxitin        | 35.1                  | 356            | 43.1    | 202     | 42.9     | 91      | 38.7     | 649      | NA <sup>3</sup> | NA  | NA     | NA     | NA        | NA      | NA       | NA       |
| Ciprofloxacin    | 28.3                  | 357            | 50.7    | 205     | 45.1     | 91      | 37.7     | 653      | 32.1            | 81  | 42.6   | 47     | 66.7      | 3       | 36.6     | 131      |
| Nitrofurantoin   | 4.5                   | 353            | 5.9     | 205     | 3.3      | 91      | 4.8      | 649      | 4.9             | 81  | 19.1   | 47     | 33.3      | 3       | 10.7     | 131      |
| Trimethoprim     | 77.9                  | 357            | 85.4    | 205     | 87.9     | 91      | 81.6     | 653      | NA              | NA  | NA     | NA     | NA        | NA      | NA       | NA       |
| Gentamicin       | 15.1                  | 357            | 23.4    | 205     | 26.6     | 64      | 19.0     | 626      | NA              | NA  | NA     | NA     | NA        | NA      | NA       | NA       |
| Linezolid        | 20.9                  | 349            | 4.9     | 205     | 7.7      | 65      | 14.2     | 619      | 15.6            | 77  | 0.0    | 41     | 0.0       | 2       | 10.0     | 120      |
| Erythromycin     | 67.4                  | 350            | 78.0    | 205     | 72.3     | 65      | 71.5     | 620      | 64.9            | 77  | 70.5   | 44     | 50.0      | 2       | 66.7     | 123      |
| Tetracycline     | 40.8                  | 358            | 53.2    | 205     | 67.7     | 65      | 47.6     | 628      | 35.0            | 80  | 63.8   | 47     | 50.0      | 2       | 45.7     | 129      |
| Vancomycin       | NA                    | NA             | NA      | NA      | NA       | NA      | NA       | NA       | 41.3            | 75  | 29.5   | 44     | 0.0       | 2       | 36.4     | 121      |
| MDR <sup>4</sup> | 53.1                  | 358            | 72.7    | 205     | 54.9     | 91      | 59.5     | 654      | 30.9            | 81  | 40.4   | 47     | 33.3      | 3       | 34.4     | 131      |

Table S9. Antibiotic susceptibility, ESBL and MDR rates of *Staphylococcus* spp. and *Enterococcus* spp. isolated from outpatients with UTI.

 $^{1}$  % is the frequency of non-susceptible isolates, expressed in percentage.

 $^{2}$  n is the total number of isolates that were tested for a specific antibiotic.

<sup>3</sup> NA: not applicable.

 $^{4}$ Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

|                  |                | Staphy         | ylococcu | s spp. (i | inpatient) |                      |        | Enter | ococcus | spp. (i | npatient) |                      |
|------------------|----------------|----------------|----------|-----------|------------|----------------------|--------|-------|---------|---------|-----------|----------------------|
| Country          | Ken            | iya            | Tanz     | ania      | Three co   | untries <sup>1</sup> | Ken    | ya    | Tanz    | ania    | Three co  | untries <sup>1</sup> |
|                  | % <sup>2</sup> | n <sup>3</sup> | %        | n         | %          | n                    | %      | n     | %       | n       | %         | n                    |
| Cefoxitin        | 67.9           | 28             | 33.3     | 15        | 55.8       | 43                   | $NA^4$ | NA    | NA      | NA      | NA        | NA                   |
| Ciprofloxacin    | 42.9           | 28             | 53.3     | 15        | 46.5       | 43                   | 60.0   | 5     | 72.7    | 11      | 68.8      | 16                   |
| Nitrofurantoin   | 17.9           | 28             | 13.3     | 15        | 16.3       | 43                   | 0.0    | 5     | 0.0     | 11      | 0.0       | 16                   |
| Trimethoprim     | 85.7           | 28             | 80.0     | 15        | 83.7       | 43                   | NA     | NA    | NA      | NA      | NA        | NA                   |
| Gentamicin       | 57.1           | 28             | 33.3     | 15        | 48.8       | 43                   | NA     | NA    | NA      | NA      | NA        | NA                   |
| Linezolid        | 55.6           | 27             | 13.3     | 15        | 40.5       | 42                   | 0.0    | 5     | 0.0     | 11      | 0.0       | 16                   |
| Erythromycin     | 85.2           | 27             | 93.3     | 15        | 88.1       | 42                   | 100    | 5     | 90.9    | 11      | 93.8      | 16                   |
| Tetracycline     | 50.0           | 28             | 60.0     | 15        | 53.5       | 43                   | 80.0   | 5     | 90.9    | 11      | 87.5      | 16                   |
| Vancomycin       | NA             | NA             | NA       | NA        | NA         | NA                   | 60.0   | 5     | 36.4    | 11      | 43.8      | 16                   |
| MDR <sup>5</sup> | 75.0           | 28             | 66.7     | 15        | 72.1       | 43                   | 60.0   | 5     | 72.7    | 11      | 68.8      | 16                   |

Table S10. Antibiotic susceptibility, ESBL and MDR rates of *Staphylococcus* spp. and *Enterococcus* spp. isolated from inpatients with UTI.

<sup>1</sup> No *Staphylococcus* or *Enterococcus* were isolated from Uganda inpatients

<sup>2</sup>% is the frequency of non-susceptible isolates, expressed in percentage.

<sup>3</sup> n is the total number of isolates that were tested for a specific antibiotic.

<sup>4</sup> NA: not applicable.

<sup>5</sup>Multi drug-resistance (MDR) was defined as non-susceptibility to at least one antimicrobial agent in three or more antimicrobial categories, according to the ECDC guidelines [10] with some modifications, as described in the methods section.

#### References (Journal of Antimicrobial Agents 40 references max.).

- World Health Organization. Antimicrobial resistance, https://www.who.int/news-room/factsheets/detail/antimicrobial-resistance; 2021 [accessed 8 March 2023].
- [2] Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022;399:629-655. https://doi.org/10.1016/S0140-6736(21)02724-0
- [3] Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al. Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture. Antimicrob Resist Infect Control 2021;10:63. https://doi.org/10.1186/s13756-021-00931-w.
- [4] Dunachie SJ, Day NP, Dolecek C. The challenges of estimating the human global burden of disease of antimicrobial resistant bacteria. Curr Opin Microbiol 2020;57:95-101. https://doi.org/10.1016/j.mib.2020.09.013
- [5] Asiimwe BB, Kiiru J, Mshana SE, Neema S, Keenan K, Kesby M, et al. Protocol for an interdisciplinary cross-sectional study investigating the social, biological and community-level drivers of antimicrobial resistance (AMR): Holistic Approach to Unravel Antibacterial Resistance in East Africa (HATUA). BMJ Open 2021;11:e041418. https://doi.org/10.1136/bmjopen-2020-041418
- [6] Öztürk R, Murt A. Epidemiology of urological infections: a global burden. World J Urol 2020;38:2669-2679. https://doi.org/10.1007/s00345-019-03071-4.
- [7] Li X, Fan H, Zi H, Hu H, Li B, Huang J, et al. Global and Regional Burden of Bacterial Antimicrobial Resistance in Urinary Tract Infections in 2019. J Clin Med 2022;11:2817. https://doi.org/10.3390/jcm11102817.
- [8] Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007;122:160-6. https://doi.org/10.1177/003335490712200205.
- [9] Malcolm W, Fletcher E, Kavanagh K, Deshpande A, Wiuff C, Marwick C, et al. Risk factors for resistance and MDR in community urine isolates: population-level analysis using the NHS Scotland Infection Intelligence Platform. J Antimicrob Chemother 2018;73:223-230. https://doi.org/10.1093/jac/dkx363.

- [10] Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
- [11] Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review. J Chemother 2017;29:2-9. https://doi.org/10.1080/1120009X.2017.1380395.
- [12] Kaye KS, Gupta V, Mulgirigama A, Joshi AV, Scangarella-Oman NE, Yu K, et al. Antimicrobial Resistance Trends in Urine Escherichia coli Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management. Clin Infect Dis 2021;73:1992-99. https://doi.org/10.1093/cid/ciab560.
- [13] Walker E, Lyman A, Gupta K, Mahoney MV, Snyder GM, Hirsch EB. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Clin Infect Dis 2016;63:960-5. https://doi.org/10.1093/cid/ciw396.
- [14] Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012;366:1028-37. https://doi.org/10.1056/NEJMcp1104429.
- [15] Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010;340:c2096. https://doi.org/10.1136/bmj.c2096.
- [16] Koneman, EW, Allen SD, Janda W, Schreckenberger P, Winn W. Diagnostic microbiology. In: The Nonfermentative Gram-Negative Bacilli, Philadelphia: Lippincott-Raven Publishers; 1997, p. 253–320.
- [17] CLSI. 2018. Performance Standards for Antimicrobial Disk Susceptibility Tests, M02, 13th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- [18] CLSI. 2021. Performance standards for antimicrobial susceptibility testing, M100, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- [19] Aanensen DM, Huntley DM, Feil EJ, al-Own F, Spratt BG. EpiCollect: linking smartphones to web applications for epidemiology, ecology and community data collection. PLoS One 2009;4:e6968. https://doi.org/10.1371/journal.pone.0006968.

- [20] Gajdács M, Bátori Z, Burián K. Interplay between Phenotypic Resistance to Relevant Antibiotics in Gram-Negative Urinary Pathogens: A Data-Driven Analysis of 10 Years' Worth of Antibiogram Data. Life (Basel) 2021;11:1059. https://doi.org/10.3390/life11101059.
- [21] Horcajada JP, Shaw E, Padilla B, Pintado V, Calbo E, Benito N, Gamallo R, Gozalo M, Rodríguez-Baño J; ITUBRAS group; Grupo de Estudio de Infección Hospitalaria (GEIH); Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect 2013 ;19:962-8. https://doi.org/10.1111/1469-0691.12089.
- [22] Ocan M, Obuku EA, Bwanga F, Akena D, Richard S, Ogwal-Okeng J, et al. Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries. BMC Public Health 2015;15:742. https://doi.org/10.1186/s12889-015-2109-3.
- [23] Do NTT, Vu HTL, Nguyen CTK, Punpuing S, Khan WA, Gyapong M, et al. Community-based antibiotic access and use in six low-income and middle-income countries: a mixed-method approach. Lancet Glob Health 2021 9:e610-e619. https://doi.org/10.1016/S2214-109X(21)00024-3.
- [24] Ndaki PM, Mushi MF, Mwanga JR, Konje ET, Ntinginya NE, Mmbaga BT, et al. Dispensing Antibiotics without Prescription at Community Pharmacies and Accredited Drug Dispensing Outlets in Tanzania: A Cross-Sectional Study. Antibiotics (Basel) 2021;10:1025. https://doi.org/10.3390/antibiotics10081025.
- [25] Low M, Neuberger A, Hooton TM, Green MS, Raz R, Balicer RD, et al. Association between urinary community-acquired fluoroquinolone-resistant Escherichia coli and neighbourhood antibiotic consumption: a population-based case-control study. Lancet Infect Dis 2019;19:419-428. https://doi.org/10.1016/S1473-3099(18)30676-5.
- [26] Keenan K, Fredricks K J, Abed Al Ahad, M, et al HATUA Consortium. Unravelling patient pathways in the context of antibacterial resistance in East Africa. https://www.researchsquare.com/article/rs-1933132/v1.
- [27] GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2022;400:2221-2248. https://doi.org/10.1016/S0140-6736(22)02185-7.

- [28] World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines (including the 22nd WHO model list of essential medicines and the 8th WHO model list of essential medicines for children), https://apps.who.int/iris/handle/10665/351172; 2021 [accessed 5 March 2023]
- [29] World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee (including the 20th WHO model list of essential medicines and the 6th model list of essential medicines for children), https://apps.who.int/iris/handle/10665/259481; 2017 [accessed 5 March 2023]
- [30] Clinical guidelines for the management and referral of common conditions at level 2-3: Primary Care. Nairobi: Ministry of Medical Services and Ministry of Public Health and Sanitation; 2009. (http://guidelines.health.go.ke:8000/media/Clinical\_Guidelines\_Vol\_II\_Final.pdf).
- [31] Standard Treatment Guidelines and National essential Medicines list for Tanzania Mainland. 2017. Ministry of Health, Community, Development, Gender, Elderly and Children (https://hssrc.tamisemi.go.tz/storage/app/uploads/public/5ab/e9b/b21/5abe9bb216267130384889.pdf).
- [32] Uganda Clinical Guidelines 2016. National Guidelines for Management of Common Conditions. Kampala: The Republic of Uganda Ministry of Health (https://www.prb.org/wpcontent/uploads/2018/05/Uganda-Clinical-Guidelines-2016-National-Guidelines-for-Management-of-Common-Conditions.pdf)
- [33] Kline KA, Lewis AL. Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract. Microbiol Spectr 2016;4: 10.1128/microbiolspec.UTI-0012-2012. https://doi.org/10.1128/microbiolspec.UTI-0012-2012.
- [34] Gajdács M, Ábrók M, Lázár A, Burián K. Increasing relevance of Gram-positive cocci in urinary tract infections: a 10-year analysis of their prevalence and resistance trends. Sci Rep 2020;10:17658. https://doi.org/10.1038/s41598-020-74834-y.
- [35] Johnson B, Stephen BM, Joseph N, Asiphas O, Musa K, Taseera K. Prevalence and bacteriology of culture-positive urinary tract infection among pregnant women with suspected urinary tract infection at Mbarara regional referral hospital, South-Western Uganda. BMC Pregnancy Childbirth 2021;21:159. https://doi.org/10.1186/s12884-021-03641-8.

- [36] Martínez-Casanova J, Gómez-Zorrilla S, Prim N, Dal Molin A, Echeverría-Esnal D, Gracia-Arnillas MP, Sendra E, Güerri-Fernández R, Durán-Jordà X, Padilla E, Horcajada JP, Grau S, Proa-Psmar Group OBOT. Risk Factors for Amoxicillin-Clavulanate Resistance in Community-Onset Urinary Tract Infections Caused by Escherichia coli or Klebsiella pneumoniae: The Role of Prior Exposure to Fluoroquinolones. Antibiotics (Basel) 2021;10:582. https://doi.org/10.3390/antibiotics10050582.
- [37] Pouwels KB, Freeman R, Muller-Pebody B, Rooney G, Henderson KL, Robotham JV, Smieszek T. Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association. J Antimicrob Chemother 2018;73:1700-1707. <u>https://doi.org/10.1093/jac/dky031</u>.